Results 111 to 120 of about 163,448 (315)

Membrane‐Permeable Nucleoside T‐1106 Diphosphate and Triphosphate Analogues as Antiviral Pronucleotides

open access: yesChemistry – A European Journal, EarlyView.
Favipiravir (T‐705) and the non‐fluorinated counterpart (T‐1106) are antiviral agents that inhibit the RNA‐dependent RNA polymerase (RdRp) of various RNA viruses. The antiviral efficacy of nucleoside analogues is strongly dependent on their intracellular activation by cellular kinases to produce their corresponding triphosphate metabolites (T‐705‐RTP ...
Chris Meier   +7 more
wiley   +1 more source

Expression, Purification, and Microscopy‐Based Assays for Engineered Recombinant Tyrosinated, Detyrosinated, and Δ2 Human Tubulin

open access: yesCytoskeleton, EarlyView.
ABSTRACT Microtubules are noncovalent polymers assembled from α/β tubulin dimers. Their structure, dynamics and interaction with effectors are regulated through the expression of diverse tubulin isotypes and chemically diverse posttranslational modifications, also known as the “tubulin code.” Understanding the biophysical correlates between tubulin ...
Jiayi Chen   +2 more
wiley   +1 more source

Electrochemical and Spectroscopic Studies of Interactions of Mn(III) Complexes with Nucleic Bases and Nucleosides [PDF]

open access: yesIranian Journal of Chemistry & Chemical Engineering, 1995
The complexes of Mn(OAc)3 and/or Mn(acac)3 with nucleic bases and nucleosides (adenine, guanine, xanthine, adenosine and guanosine) have been synthesized in nonaqueous solution.
Davar Mohammadi Boghai   +2 more
doaj  

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi   +5 more
wiley   +1 more source

Front Cover: Sustainability and Chaos in the Abiotic Polymerization of 3′,5′ Cyclic Guanosine Monophosphate: The Role of Aggregation (ChemSystemsChem 1/2021) [PDF]

open access: bronze, 2020
Giovanna Costanzo   +9 more
openalex   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu   +5 more
wiley   +1 more source

Purine metabolism rewiring improves glioblastoma susceptibility to temozolomide treatment

open access: yesCell Death and Disease
Glioblastoma (GBM) is among the deadliest cancers, characterized by poor prognosis and median survival of 12–15 months post-diagnosis. Despite aggressive therapeutic regimens, GBM treatment is still an unmet clinical need due to heterogeneity ...
Simona D’Aprile   +17 more
doaj   +1 more source

Self-assembled guanosine-hydrogels for drug-delivery application: Structural and mechanical characterization, methylene blue loading and controlled release

open access: green, 2020
Juliana Sakamoto Yoneda   +8 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy